Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults

[1]  Publisher'sNote , 2019, Management Accounting Research.

[2]  S. Mikhalovsky,et al.  Investigation of the adsorption capacity of the enterosorbent Enterosgel for a range of bacterial toxins, bile acids and pharmaceutical drugs , 2019, Scientific reports.

[3]  A. Kemppinen,et al.  Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial , 2019, BMJ open gastroenterology.

[4]  D. S. Ahmed,et al.  A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome , 2018, BMC Gastroenterology.

[5]  Publisher's Note , 2018, Anaesthesia.

[6]  W. Chey,et al.  Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use , 2017, The American Journal of Gastroenterology.

[7]  Tao-Tao Liu,et al.  Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[8]  Javier Santos,et al.  Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome , 2017, Journal of gastroenterology and hepatology.

[9]  R. Spiller.  Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment , 2016, F1000Research.

[10]  Lin Chang,et al.  Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. , 2016, Gastroenterology.

[11]  R. Spiller,et al.  Bowel Disorders. , 2016, Gastroenterology.

[12]  J. West,et al.  Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment , 2015, PharmacoEconomics.

[13]  M. El-Salhy.  Recent developments in the pathophysiology of irritable bowel syndrome. , 2015, World journal of gastroenterology.

[14]  Jacob E. Kurlander,et al.  Irritable bowel syndrome: a clinical review. , 2015, JAMA.

[15]  N. Lonardo,et al.  Ventricular Tachycardia Associated with High‐Dose Chronic Loperamide Use , 2015, Pharmacotherapy.

[16]  L. Saha.  Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. , 2014, World journal of gastroenterology.

[17]  M. Pimentel,et al.  Placebo Effect in Clinical Trial Design for Irritable Bowel Syndrome , 2014, Journal of neurogastroenterology and motility.

[18]  Joe West,et al.  The epidemiology of irritable bowel syndrome , 2014, Clinical epidemiology.

[19]  I. Hall,et al.  A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea , 2013, Gut.

[20]  C. Olano,et al.  Management of irritable bowel syndrome in primary care , 2013 .

[21]  A. Ford,et al.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  K. Olden.  Targeted therapies for diarrhea-predominant irritable bowel syndrome , 2012, Clinical and experimental gastroenterology.

[23]  J. Tack,et al.  Randomised clinical trial: the safety and efficacy of AST‐120 in non‐constipating irritable bowel syndrome – a double‐blind, placebo‐controlled study , 2011, Alimentary pharmacology & therapeutics.

[24]  A. Ford,et al.  Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents , 2011, Therapeutic advances in gastroenterology.

[25]  L. Öhman,et al.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions , 2010, Nature Reviews Gastroenterology &Hepatology.

[26]  D. Drossman,et al.  Functional Bowel Disorders , 1995, The American Journal of Gastroenterology.

[27]  F. Guarner,et al.  Irritable bowel syndrome : a global perspective. , 2009 .

[28]  Chih‐Yen Chen,et al.  Efficacy of dioctahedral smectite in treating patients of diarrhea‐predominant irritable bowel syndrome , 2007, Journal of gastroenterology and hepatology.

[29]  R Jones,et al.  Guidelines on the irritable bowel syndrome: mechanisms and practical management , 2007, Gut.

[30]  A. Lowry.  International Foundation for Functional Gastrointestinal Disorders , 2006 .

[31]  S. Sullivan,et al.  Total costs of IBS: employer and managed care perspective. , 2005, The American journal of managed care.

[32]  M. Heyman,et al.  Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha. , 1997, Gut.